Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"SARS-CoV-2 infected cells" is a collective term describing any cell that has been invaded by the SARS-CoV-2 virus, the causative agent of COVID-19. This phrase does not specify a single molecular entity or receptor but rather denotes the infection state of various cell types susceptible to viral entry and replication. SARS-CoV-2 infection leads to characteristic changes in host cells, involving expression of viral proteins, altered host gene expression, and disruptions in cellular and organelle function. The virus typically gains entry via angiotensin-converting enzyme 2 (ACE2) and may use other co-receptors. 'SARS-CoV-2 infected cells' is not a molecularly defined therapeutic target, but rather a descriptive category useful for clinical diagnostics, research studies, or therapeutic context when targeting infected rather than uninfected cells."[1][2][4][5][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SARS-CoV-2 infected cells.